NASDAQ · Biotechnology

ALXO (ALXO) Stock

$1.95 -2.26% NASDAQ: ALXO Healthcare

Valuation

MetricValue
Price$1.95
Market Cap$261.72M
P/E Ratio-1.04
P/B Ratio4.12
P/S Ratio0.00
EPS (TTM)$-1.90
52-Week High$2.66
52-Week Low$0.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-392.31%
ROA-172.88%
ROCE-400.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio2.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-84.0M$-127.0M$-170.0M$-142.0M$-104.0M
Net Profit$-83.0M$-123.0M$-161.0M$-135.0M$-102.0M
EPS$-2.07$-3.03$-3.74$-2.58$-1.90
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$380.0M$306.0M$243.0M$148.0M$59.0M
Total Liabilities$17.0M$43.0M$53.0M$34.0M$33.0M
Cash$364.0M$49.0M$22.0M$18.0M$16.0M
Borrowings$1.0M$10.0M$17.0M$17.0M$5.0M

Latest News

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? Zacks · Jul 9, 2026 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules GlobeNewswire · Jun 30, 2026 ALX Oncology Appoints Scott Garland as Board Chairman MT Newswires · Jun 30, 2026 ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel GlobeNewswire · Jun 30, 2026 ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs MarketBeat · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-89.0M$-130.0M$-122.0M$-84.0M
Investing Cash Flow$-10.0M$-237.0M$43.0M$86.0M$82.0M
Financing Cash Flow$0$-1.0M$1.0M$0$0
Net Cash Flow$-71.0M$-315.0M$-26.0M$-5.0M$-1.0M
Free Cash Flow$-73.0M$-91.0M$-132.0M$-122.0M$-84.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-72.59%
Quick Ratio7.21
Interest Coverage-52.00
Return 1Y299.21%
Return 3Y-67.21%
Return 5Y-96.19%

Ownership

Insiders Held0.92%
Institutions Held78.79%
Institutions Float Held79.52%
Institutional HolderSharesReport Date
RA Capital Management, L.P.13,011,8492026-03-31
TCG Crossover Management, LLC13,011,8492026-03-31
venBio Partners LLC12,884,6382026-03-31
Redmile Group, LLC7,964,1882026-03-31
Blackstone Inc5,826,5442026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ALXO

ALXO is led by CEO Jason W. Lettmann, employs 65 people, headquartered in US, publicly traded since 2020.

ALXO stock trades at $1.95 with a market capitalization of $261.72M. The stock is valued at a price-to-earnings (P/E) ratio of -1.04, price-to-book of 4.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.40 and $2.66, and currently trades 26.7% below its 52-week high.

On profitability, ALXO generates a return on equity (ROE) of -392.31%, return on capital employed of -400.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides